Pfizer Vaccine Effective, Well-tolerated in Adolescents, Company Says
Results of a Phase 3 trial of Pfizer/BioNTech's COVID-19 vaccine demonstrated a 100% efficacy and robust antibody responses in participants aged 12-15 years old, according to the company.